MEDICENNA REPORTS MORE THAN DOUBLING OF MEDIAN OVERALL SURVIVAL IN GLIOBLASTOMA PATIENTS WITH UNRESECTABLE RECURRENT IDH-WT TUMORS FOLLOWING ONE TREATMENT WITH BIZAXOFUSP VERSUS A MATCHED EXTERNAL CONTROL AT SNO 2026

Reuters · 1d ago

Please log in to view news